Objective To evaluate the effectiveness of agomelatine in the treatment of anhedonia in patients with depressive disorders. Methods A total of 58 subjects were included in the study. All patients were treated with agomelatin（ 25-50 mg/d， variable doses） for 8 weeks. Snaith-Hamilton Pleasure Scale（ SHAPS） and Montgomery-Åsberg Depression Rating Scale（ MADRS） were used to evaluate patients' depression and anhedonia， and the Sheehan Disability Scale（ SDS） and the 5-Item World Health Organization Well-Being Index （WHO-5） were used to evaluate patients' functional impairment and quality of life. Results （1）After 8 weeks of treatment with agomelatin， the clinical response and remission rates of SHAPS were 64.71%（33/51） and 58.82% （30/51）. The SHAPS and MADRS anhedonia factors after the treatment were significantly improved compared to baseline（ P ＜ 0.01）.（ 2）Regression analysis showed that gender， first-episode age and family history of mental illness affected the improvement of anhedonia.（ 3）At the end of 8 weeks of treatment， the improvement of SHAPS and MADRS anhedonia factor was significantly correlated with the improvement of WHO-5 and SDS scores（ P＜0.01）.（ 4）Mediational effect analysis showed that the improvement in anhedonia mediated the relationship between depressive severity and the improvement of social functions. Conclusions Agomelatin has a significant effect on anhedonia in patients with depressive disorder， and the improvement of anhedonia is a powerful mediator for the relationship between depressive symptoms and the improvement of social functions.